Studies show prognostic value for circulating tumor cells in advanced prostate and br

[News]

Menarini Silicon Biosystems, the pioneer of liquid biopsy and single cell technologies, announced today that results from a new study presented at the virtual 2020 meeting of the American Society of Clinical Oncology suggest that circulating tumor cell counts may be useful in determining long-term prognosis and guiding treatment selection in patients with metastatic castrate sensitive prostate cancer.

More... (https://www.news-medical.net/news/20200610/Studies-show-prognostic-value-for-circulating-tumor-cells-in-advanced-prostate-and-breast-cancer.aspx)